ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . New York, New York--(Newsfile Corp. - August 2, 2026) - Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants' statements about ADMA Biologics' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On March 24, 2026, Culper Research, an investigative research firm, published a report titled "ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported." The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to "stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations." This allegedly allowed ADMA Biologics to book revenue and "report[] growth that was never there." According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth. This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding ADMA Biologics' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the ADMA Biologics class action, go to www.faruqilaw.com/[ADMA](/en/us/ADMA) or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . What is the ADMA Biologics securities fraud lawsuit about? The lawsuit alleges that ADMA Biologics and certain executives made materially false and misleading statements and failed to disclose key information about the Company's business and financial practices. Specifically, the ...